zurück

Bimekizumab (moderate to severe plaque psoriasis)

Subject:

  • Active Substance: Bimekizumab
  • Name: Bimzelx®
  • Therapeutic area: Plaque psoriasis
  • Pharmaceutical company: UCB Pharma GmbH

Time table:

  • Start: 15.09.2021
  • Final decision by G-BA: 03.03.2022

Final decision:

  • Patients with moderate to severe plaque psoriasis who are not eligible for conventional therapy in the setting of initial systemic therapy: Indication for a minor additional benefit
  • Patients with moderate to severe plaque psoriasis who have had an inadequate response to or have not tolerated systemic therapy: Indication for a minor additional benefit